TY  - BOOK
AU  - Property,World Intellectual
TI  - COVID-19-Related Vaccines and Therapeutics: Preliminary Insights on Related Patenting Activity During the Pandemic
SN  - 9789280533606
PY  - 2022///
CY  - Geneva
PB  - World Intellectual Property Organization
KW  - COVID-19 (Disease)
KW  - Electronic books
N1  - Intro -- _Hlk93048502 -- Acknowledgements -- Key findings -- Introduction -- Background -  biology of COVID-19 -- Overview of patenting activity related to COVID-19 -- Patent filings during 2020-2021 -- Filing and publication of COVID-19-related patent applications over time -- COVID-19-related vaccine and therapeutic patent applicant profiles -- Research collaboration and IP strategies related to technologies important to COVID-19 vaccines and therapeutics -- Disclosure of sequences within patent documents -- COVID-19 vaccines -- Background - vaccine platforms -- Conventional vaccine platforms -- Novel vaccine platforms -- Patent and vaccine distribution by vaccine platform and published applicant location -- Speed of vaccine development -- COVID-19 vaccine patent landscape -- Core vaccine technologies, collaboration and licensing -- Analysis of WHO data on COVID-19 vaccines -- Timelines on key technologies for COVID-19 vaccine development -- Technologies relevant to mRNA vaccine -- Timeline details for adenovirus vaccine development -- Timeline details for vaccine adjuvant development -- COVID-19 therapeutics -- Background -- Analysis of COVID-19 therapeutics-related patent applications by substances type -- Top locations of patent applicants for COVID-19 therapeutics and their filing strategies -- Highlights of patent filings related to COVID-19 therapeutic development -- Patent filings related to development of small-molecule drugs for COVID-19 -- Patent filings related to the development of biologics for COVID-19 -- Patents related to antibodies for COVID-19 treatment -- Peptide and protein therapies -- Nucleic-acid-based therapies -- Aptamer-mediated therapy -- Cell-based therapies -- Other biologic-based therapies -- Analysis of COVID-19 therapeutics in clinical trials; Analysis of COVID-19 therapeutics data in the Milken Institute and Regulatory Affairs Professionals Society (RAPS) tracker data -- Distribution of COVID-19 drug candidates across small molecules and biologics, repurposed drugs and de novo synthesized drugs -- Classification of COVID-19 drug candidates in clinical trials by molecular nature and function -- Feature summary of examples of anti-COVID-19 drug candidates in clinical trials -- Perspectives -- Annex -- Data sources and methods -- Tables of vaccine types and candidates currently in clinical trials -- Examples of partial, early disclosure observed at the Israeli, U.K. and Singapore patent offices -- Glossary -- References -- Further reading
UR  - https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=7113890
ER  -